User:R. Jeremy Johnson/ABCG2 Transporter - Revision history

R. Jeremy Johnson at 14:26, 3 December 2020

R. Jeremy Johnson — Thu, 03 Dec 2020 14:26:47 GMT

←Older revision		Revision as of 14:26, 3 December 2020
Line 8:		Line 8:
	The [https://en.wikipedia.org/wiki/ABCG2 ABCG2 multidrug transporter] is a membrane protein from the '''A'''TP-'''B'''inding '''C'''assette [https://en.wikipedia.org/wiki/ATP-binding_cassette_transporter (ABC)] transporter family, specifically the G-subfamily. Also known as the breast cancer resistance protein (BCRP), ABCG2 has physiological roles in various tissue cells including the [https://en.wikipedia.org/wiki/Mammary_gland mammary gland] and the [https://en.wikipedia.org/wiki/Blood%E2%80%93brain_barrier blood-brain], [https://en.wikipedia.org/wiki/Blood%E2%80%93testis_barrier blood-testis], and [https://en.wikipedia.org/wiki/Placenta maternal-fetal] barriers.<ref name="Taylor">PMID:28554189</ref> ABCG2 protects cells by exporting [https://en.wikipedia.org/wiki/Xenobiotic xenobiotic] molecules out of the cell using ATP hydrolysis. ABCG2 also affects the [https://en.wikipedia.org/wiki/Pharmacokinetics pharmacokinetics] of many drugs and contributes to [https://en.wikipedia.org/wiki/Multiple_drug_resistance multidrug resistance].<ref name="Manolaridis">PMID:30405239</ref> ABCG2 belongs to the family of 48 transporter proteins called ATP-binding cassette transporters (ABC transporters). A high percentage of the ABC family transporters (19 of the 48) transport [https://en.wikipedia.org/wiki/List_of_chemotherapeutic_agents chemotherapeutic agents] out of cells, making expression levels of ABC transporters a major indicator of cancer treatment prognosis.<ref name="Robey">PMID:29643473</ref>		The [https://en.wikipedia.org/wiki/ABCG2 ABCG2 multidrug transporter] is a membrane protein from the '''A'''TP-'''B'''inding '''C'''assette [https://en.wikipedia.org/wiki/ATP-binding_cassette_transporter (ABC)] transporter family, specifically the G-subfamily. Also known as the breast cancer resistance protein (BCRP), ABCG2 has physiological roles in various tissue cells including the [https://en.wikipedia.org/wiki/Mammary_gland mammary gland] and the [https://en.wikipedia.org/wiki/Blood%E2%80%93brain_barrier blood-brain], [https://en.wikipedia.org/wiki/Blood%E2%80%93testis_barrier blood-testis], and [https://en.wikipedia.org/wiki/Placenta maternal-fetal] barriers.<ref name="Taylor">PMID:28554189</ref> ABCG2 protects cells by exporting [https://en.wikipedia.org/wiki/Xenobiotic xenobiotic] molecules out of the cell using ATP hydrolysis. ABCG2 also affects the [https://en.wikipedia.org/wiki/Pharmacokinetics pharmacokinetics] of many drugs and contributes to [https://en.wikipedia.org/wiki/Multiple_drug_resistance multidrug resistance].<ref name="Manolaridis">PMID:30405239</ref> ABCG2 belongs to the family of 48 transporter proteins called ATP-binding cassette transporters (ABC transporters). A high percentage of the ABC family transporters (19 of the 48) transport [https://en.wikipedia.org/wiki/List_of_chemotherapeutic_agents chemotherapeutic agents] out of cells, making expression levels of ABC transporters a major indicator of cancer treatment prognosis.<ref name="Robey">PMID:29643473</ref>

-	Using [https://en.wikipedia.org/wiki/Cryogenic_electron_microscopy cryoelectron microscopy] (cryo-EM), the two cavity substrate transport structure (<scene name='83/832932/Highlight_cavity_1/3'>Cavity 1</scene>; <scene name='83/832932/Atp_bound_use_cav_2/3'>Cavity 2</scene>), inward facing nucleotide binding domain (<scene name='83/832932/Overall_structure_nbd_unbound/6'>NBD</scene>), and condensed extracellular loop 3 (<scene name='83/832939/El-3/3'>EL-3</scene>) structure of ABCG2 have been elucidated. These structures also illustrated the transporter cycle of ABCG2, the binding locations for inhibitors, and the link between cancer and the ABC transporter family.<ref name="Taylor"/><ref name="Manolaridis"/><ref name="Jackson"/>	+	Using [https://en.wikipedia.org/wiki/Cryogenic_electron_microscopy cryoelectron microscopy] (cryo-EM), the two cavity substrate transport structure (<scene name='83/832932/Highlight_cavity_1/3'>Cavity 1</scene>; <scene name='83/832932/Atp_bound_use_cav_2/3'>Cavity 2</scene>), inward facing nucleotide binding domain (<scene name='83/832932/Overall_structure_nbd_unbound/6'>NBD</scene>), and condensed extracellular loop 3 (<scene name='83/832939/El-3/3'>EL-3</scene>) structure of ABCG2 have been elucidated. These structures also illustrated the transporter cycle of ABCG2, the binding locations for inhibitors, and the link between cancer and the ABC transporter family.<ref name="Taylor"/><ref name="Manolaridis"/><ref name="Jackson">PMID:29610494</ref>

	== Structural highlights ==		== Structural highlights ==

R. Jeremy Johnson at 14:22, 3 December 2020

R. Jeremy Johnson — Thu, 03 Dec 2020 14:22:46 GMT

←Older revision		Revision as of 14:22, 3 December 2020
Line 19:		Line 19:
	When ATP binds, α-helices in the NBD <scene name='83/832932/Atp_bound_nbd/3'>rotate</scene> approximately 35° relative to the <scene name='83/832932/Overall_structure_nbd_unbound/5'>inward-facing conformation of NBD</scene>. This shift in the NBD causes slight shifts of α-helices in the TMD; these helices are <scene name='83/832932/Atp_bound_use_tmd/4'>pushed toward each other</scene> relative to the <scene name='83/832932/Overall_structure_tmd_unbound/4'>inward-facing conformation of TMD</scene>. The overall shift from inward-facing to outward-facing promotes the transport of substrates through the transporter.<ref name="Manolaridis"/>		When ATP binds, α-helices in the NBD <scene name='83/832932/Atp_bound_nbd/3'>rotate</scene> approximately 35° relative to the <scene name='83/832932/Overall_structure_nbd_unbound/5'>inward-facing conformation of NBD</scene>. This shift in the NBD causes slight shifts of α-helices in the TMD; these helices are <scene name='83/832932/Atp_bound_use_tmd/4'>pushed toward each other</scene> relative to the <scene name='83/832932/Overall_structure_tmd_unbound/4'>inward-facing conformation of TMD</scene>. The overall shift from inward-facing to outward-facing promotes the transport of substrates through the transporter.<ref name="Manolaridis"/>

-	The NBDs in ABCG2 remain in contact with one another even without a bound substrate, providing greater substrate specificity as the entrance to the transporter is not as globular as other ABC transporters like ABCB1 or ABCC1. The entrance from the cytoplasm to the transporter is lined by [https://en.wikipedia.org/wiki/Hydrophobe hydrophobic] residues<scene name='83/832939/Lining_of_entrance_of_nbd/1'> A397, V401, L405, L539, I543 and T547</scene> in both [https://en.wikipedia.org/wiki/Monomer monomers]. Dimerization of ABCG2 was originally hypothesized to require a <scene name='83/832939/Disproved_dimerization_process/1'>406xxx410 structural motif</scene> in each of the two domains. Cryo-EM structures however showed that these structural [https://en.wikipedia.org/wiki/Sequence_motif motifs] were on opposite sides of the protein.<ref name="Manolaridis" /> <ref name="Jackson">PMID:29610494</ref>	+	The NBDs in ABCG2 remain in contact with one another even without a bound substrate, providing greater substrate specificity as the entrance to the transporter is not as globular as other ABC transporters like ABCB1 or ABCC1. The entrance from the cytoplasm to the transporter is lined by [https://en.wikipedia.org/wiki/Hydrophobe hydrophobic] residues<scene name='83/832939/Lining_of_entrance_of_nbd/1'> A397, V401, L405, L539, I543 and T547</scene> in both [https://en.wikipedia.org/wiki/Monomer monomers].

	===Cavities and Leucine Plug===		===Cavities and Leucine Plug===

R. Jeremy Johnson at 14:19, 3 December 2020

R. Jeremy Johnson — Thu, 03 Dec 2020 14:19:59 GMT

←Older revision		Revision as of 14:19, 3 December 2020
Line 8:		Line 8:
	The [https://en.wikipedia.org/wiki/ABCG2 ABCG2 multidrug transporter] is a membrane protein from the '''A'''TP-'''B'''inding '''C'''assette [https://en.wikipedia.org/wiki/ATP-binding_cassette_transporter (ABC)] transporter family, specifically the G-subfamily. Also known as the breast cancer resistance protein (BCRP), ABCG2 has physiological roles in various tissue cells including the [https://en.wikipedia.org/wiki/Mammary_gland mammary gland] and the [https://en.wikipedia.org/wiki/Blood%E2%80%93brain_barrier blood-brain], [https://en.wikipedia.org/wiki/Blood%E2%80%93testis_barrier blood-testis], and [https://en.wikipedia.org/wiki/Placenta maternal-fetal] barriers.<ref name="Taylor">PMID:28554189</ref> ABCG2 protects cells by exporting [https://en.wikipedia.org/wiki/Xenobiotic xenobiotic] molecules out of the cell using ATP hydrolysis. ABCG2 also affects the [https://en.wikipedia.org/wiki/Pharmacokinetics pharmacokinetics] of many drugs and contributes to [https://en.wikipedia.org/wiki/Multiple_drug_resistance multidrug resistance].<ref name="Manolaridis">PMID:30405239</ref> ABCG2 belongs to the family of 48 transporter proteins called ATP-binding cassette transporters (ABC transporters). A high percentage of the ABC family transporters (19 of the 48) transport [https://en.wikipedia.org/wiki/List_of_chemotherapeutic_agents chemotherapeutic agents] out of cells, making expression levels of ABC transporters a major indicator of cancer treatment prognosis.<ref name="Robey">PMID:29643473</ref>		The [https://en.wikipedia.org/wiki/ABCG2 ABCG2 multidrug transporter] is a membrane protein from the '''A'''TP-'''B'''inding '''C'''assette [https://en.wikipedia.org/wiki/ATP-binding_cassette_transporter (ABC)] transporter family, specifically the G-subfamily. Also known as the breast cancer resistance protein (BCRP), ABCG2 has physiological roles in various tissue cells including the [https://en.wikipedia.org/wiki/Mammary_gland mammary gland] and the [https://en.wikipedia.org/wiki/Blood%E2%80%93brain_barrier blood-brain], [https://en.wikipedia.org/wiki/Blood%E2%80%93testis_barrier blood-testis], and [https://en.wikipedia.org/wiki/Placenta maternal-fetal] barriers.<ref name="Taylor">PMID:28554189</ref> ABCG2 protects cells by exporting [https://en.wikipedia.org/wiki/Xenobiotic xenobiotic] molecules out of the cell using ATP hydrolysis. ABCG2 also affects the [https://en.wikipedia.org/wiki/Pharmacokinetics pharmacokinetics] of many drugs and contributes to [https://en.wikipedia.org/wiki/Multiple_drug_resistance multidrug resistance].<ref name="Manolaridis">PMID:30405239</ref> ABCG2 belongs to the family of 48 transporter proteins called ATP-binding cassette transporters (ABC transporters). A high percentage of the ABC family transporters (19 of the 48) transport [https://en.wikipedia.org/wiki/List_of_chemotherapeutic_agents chemotherapeutic agents] out of cells, making expression levels of ABC transporters a major indicator of cancer treatment prognosis.<ref name="Robey">PMID:29643473</ref>

-	Using [https://en.wikipedia.org/wiki/Cryogenic_electron_microscopy cryoelectron microscopy] (cryo-EM), the two cavity substrate transport structure (<scene name='83/832932/Highlight_cavity_1/3'>Cavity 1</scene>; <scene name='83/832932/Atp_bound_use_cav_2/3'>Cavity 2</scene>), inward facing nucleotide binding domain (<scene name='83/832932/Overall_structure_nbd_unbound/6'>NBD</scene>), and condensed extracellular loop 3 (<scene name='83/832939/El-3/3'>EL-3</scene>) structure of ABCG2 have been elucidated. These structures also illustrated the transporter cycle of ABCG2, the binding locations for inhibitors, and the link between cancer and the ABC transporter family.<ref name="~~Manolaridis~~"/><ref name="~~Taylor~~"/><ref name="Jackson"/>	+	Using [https://en.wikipedia.org/wiki/Cryogenic_electron_microscopy cryoelectron microscopy] (cryo-EM), the two cavity substrate transport structure (<scene name='83/832932/Highlight_cavity_1/3'>Cavity 1</scene>; <scene name='83/832932/Atp_bound_use_cav_2/3'>Cavity 2</scene>), inward facing nucleotide binding domain (<scene name='83/832932/Overall_structure_nbd_unbound/6'>NBD</scene>), and condensed extracellular loop 3 (<scene name='83/832939/El-3/3'>EL-3</scene>) structure of ABCG2 have been elucidated. These structures also illustrated the transporter cycle of ABCG2, the binding locations for inhibitors, and the link between cancer and the ABC transporter family.<ref name="Taylor"/><ref name="Manolaridis"/><ref name="Jackson"/>

	== Structural highlights ==		== Structural highlights ==

R. Jeremy Johnson at 14:19, 3 December 2020

R. Jeremy Johnson — Thu, 03 Dec 2020 14:19:28 GMT

(Difference between revisions)

R. Jeremy Johnson at 16:53, 5 May 2020

R. Jeremy Johnson — Tue, 05 May 2020 16:53:11 GMT

←Older revision		Revision as of 16:53, 5 May 2020
Line 55:		Line 55:
	==Student Contributors==		==Student Contributors==
	Julia Pomeroy		Julia Pomeroy
		+
	Shelby Skaggs		Shelby Skaggs
		+
	Sam Sullivan		Sam Sullivan
		+
	Jaelyn Voyles		Jaelyn Voyles

R. Jeremy Johnson at 14:42, 5 May 2020

R. Jeremy Johnson — Tue, 05 May 2020 14:42:29 GMT

←Older revision		Revision as of 14:42, 5 May 2020
Line 30:		Line 30:

	===Structural Elucidation of ABCG2===		===Structural Elucidation of ABCG2===
-	Binding of two antigen binding fragments <scene name='83/832939/Abcg2_with_bound_5d3-fab/4'>(5D3-Fab)</scene> were required for stabilization of ABCG2 for high resolution cryo-EM images to be developed for the ABCG2 transporter protein.<ref name="Taylor"/><ref name="Manolaridis"/> 5D3 Fab <scene name='83/832939/Fab_binding_site/2'>clamps</scene> the two domains together preventing movement of the transporter from inward to outward facing. Fab binds at a 35 degree angle relative to the membrane plane which stops the 40 degree transition of the TMD from closed to open. Interestingly, complete arrest of ABCG2 in its inward facing state only requires one Fab bound but in experiments, two Fabs bound, each to both domains.<ref name="Taylor"/><ref name="Manolaridis"/>	+	Binding of two antigen binding fragments (<scene name='83/832939/Abcg2_with_bound_5d3-fab/4'>5D3-Fab</scene>) were required for stabilization of ABCG2 for high resolution cryo-EM images to be developed for the ABCG2 transporter protein.<ref name="Taylor"/><ref name="Manolaridis"/> 5D3 Fab <scene name='83/832939/Fab_binding_site/2'>clamps</scene> the two domains together preventing movement of the transporter from inward to outward facing. Fab binds at a 35 degree angle relative to the membrane plane which stops the 40 degree transition of the TMD from closed to open. Interestingly, complete arrest of ABCG2 in its inward facing state only requires one Fab bound but in experiments, two Fabs bound, each to both domains.<ref name="Taylor"/><ref name="Manolaridis"/>

	==Disease==		==Disease==

R. Jeremy Johnson at 14:41, 5 May 2020

R. Jeremy Johnson — Tue, 05 May 2020 14:41:37 GMT

←Older revision		Revision as of 14:41, 5 May 2020
Line 27:		Line 27:
	After substrates bind in Cavity 1, ATP binds each NBD leading to the transporter shifting from inward-facing to outward-facing. The outward-facing conformation results in the <scene name='83/832932/Atp_bound_cavity_2/3'>collapse of Cavity 1</scene> in the TMD in which the cavity is no longer <scene name='83/832932/Overall_structure_cavity_1hel/4'>open to the cytosol</scene>. This collapse forces the substrate to move forward to Cavity 2 as there is no longer room in Cavity 1 to accommodate substrates.<ref name="Manolaridis"/> <scene name='83/832932/Atp_bound_use_cav_2/3'>Cavity 2</scene>, which is occluded when the protein in is the inward-facing conformation, is now open to the extracellular space and able to release the substrate. Cavity 2 contains a less hydrophobic environment and, as a result, substrates are released due to hydrophobic mismatch.<ref name="Taylor"/> <scene name='83/832932/Atp_bound_use_el_disulfides/3'>Disulfide bonds</scene> in the external loops near the exit of Cavity 2 also help promote substrate release.<ref name="Manolaridis"/> Once Cavity 2 is empty, the protein reverts to the inward-facing conformation via hydrolysis of ATP.		After substrates bind in Cavity 1, ATP binds each NBD leading to the transporter shifting from inward-facing to outward-facing. The outward-facing conformation results in the <scene name='83/832932/Atp_bound_cavity_2/3'>collapse of Cavity 1</scene> in the TMD in which the cavity is no longer <scene name='83/832932/Overall_structure_cavity_1hel/4'>open to the cytosol</scene>. This collapse forces the substrate to move forward to Cavity 2 as there is no longer room in Cavity 1 to accommodate substrates.<ref name="Manolaridis"/> <scene name='83/832932/Atp_bound_use_cav_2/3'>Cavity 2</scene>, which is occluded when the protein in is the inward-facing conformation, is now open to the extracellular space and able to release the substrate. Cavity 2 contains a less hydrophobic environment and, as a result, substrates are released due to hydrophobic mismatch.<ref name="Taylor"/> <scene name='83/832932/Atp_bound_use_el_disulfides/3'>Disulfide bonds</scene> in the external loops near the exit of Cavity 2 also help promote substrate release.<ref name="Manolaridis"/> Once Cavity 2 is empty, the protein reverts to the inward-facing conformation via hydrolysis of ATP.

-	Cavities 1 and 2 are separated by a <scene name='83/832932/Leucine_plug_open_con/7'>leucine plug</scene> which likely acts as a substrate check-point during transport; changes to either of these leucine residues have exhibited an increase in transport and a decrease in substrate specificity.<ref name="Manolaridis"/> After the substrate binds Cavity 1 and ATP molecules bind each NBD, the <scene name='83/832932/Atp_bound_cavsleu/5'>leucine plug opens</scene> to allow the substrate to enter Cavity 2. Once the substrate enters Cavity 2, the plug is able to reform and promote substrate release and conversion to the inward-facing conformation.	+	Cavities 1 and 2 are separated by a <scene name='83/832932/Leucine_plug_open_con/7'>leucine plug</scene> which likely acts as a substrate check-point during transport; changes to either of these leucine residues have exhibited an increase in transport and a decrease in substrate specificity.<ref name="Manolaridis"/> After the substrate binds Cavity 1 and ATP molecules bind each NBD, the <scene name='83/832932/Atp_bound_cavsleu/5'>leucine plug opens</scene> to allow the substrate to enter Cavity 2. Once the substrate enters Cavity 2, the plug is able to reform and promote substrate release and conversion to the inward-facing conformation.
		+
		+	===Structural Elucidation of ABCG2===
		+	Binding of two antigen binding fragments <scene name='83/832939/Abcg2_with_bound_5d3-fab/4'>(5D3-Fab)</scene> were required for stabilization of ABCG2 for high resolution cryo-EM images to be developed for the ABCG2 transporter protein.<ref name="Taylor"/><ref name="Manolaridis"/> 5D3 Fab <scene name='83/832939/Fab_binding_site/2'>clamps</scene> the two domains together preventing movement of the transporter from inward to outward facing. Fab binds at a 35 degree angle relative to the membrane plane which stops the 40 degree transition of the TMD from closed to open. Interestingly, complete arrest of ABCG2 in its inward facing state only requires one Fab bound but in experiments, two Fabs bound, each to both domains.<ref name="Taylor"/><ref name="Manolaridis"/>

	==Disease==		==Disease==
	[[Image:Ligand_Interactions_6ffc.png\|400 px\|right\|thumb\|Figure 3: MZ29 bound to cavity 1 of ABCG2 [https://www.rcsb.org/structure/6FFC (6FFC)]. Two MZ29 are shown in sticks and are colored by element. Hydrophobic interactions between the surface of cavity 1 and MZ29 are shown in green.]]		[[Image:Ligand_Interactions_6ffc.png\|400 px\|right\|thumb\|Figure 3: MZ29 bound to cavity 1 of ABCG2 [https://www.rcsb.org/structure/6FFC (6FFC)]. Two MZ29 are shown in sticks and are colored by element. Hydrophobic interactions between the surface of cavity 1 and MZ29 are shown in green.]]
	Dysfunctions in ABCG2 are linked to [https://en.wikipedia.org/wiki/Hyperuricemia hyperuricemia] which can lead to [https://en.wikipedia.org/wiki/Gout gout], [https://en.wikipedia.org/wiki/Kidney_disease kidney disease], and [https://en.wikipedia.org/wiki/Hypertension hypertension], all of which are thought to be the result of impaired transport of uric acid. Additionally, the expression of ABCG2 has been found to correlate with a poor prognosis and treatment outcome of various cancers including breast, ovarian, and lung.<ref name="Jackson"/>		Dysfunctions in ABCG2 are linked to [https://en.wikipedia.org/wiki/Hyperuricemia hyperuricemia] which can lead to [https://en.wikipedia.org/wiki/Gout gout], [https://en.wikipedia.org/wiki/Kidney_disease kidney disease], and [https://en.wikipedia.org/wiki/Hypertension hypertension], all of which are thought to be the result of impaired transport of uric acid. Additionally, the expression of ABCG2 has been found to correlate with a poor prognosis and treatment outcome of various cancers including breast, ovarian, and lung.<ref name="Jackson"/>
		+
		+	Several mutations also decrease transporter activity.<ref name="Taylor"/><ref name="Manolaridis"/><ref name="Robey"/> The most detrimental of these is a point mutation of <scene name='83/832939/Residue_211/1'>Glu 211</scene> to Gln 211, which completely abolished activity of the transporter. Another point mutation occurs at Gln141 (<scene name='83/832939/The_cause_of_gout/1'>Q141</scene>), which when mutated to lysine causes gout by distorting ABCG2's tertiary structure. Changes at <scene name='83/832939/R482/1'>Arg482</scene> shift the substrate specificity of ABCG2 by allosteric effects as this residue is distantly located from the binding pocket.

	===Cancer===		===Cancer===
Line 44:		Line 49:
	While ABC transporter inhibition was dismissed after failed clinical trials, interest in revisiting ABC inhibition has reemerged due to new developments made in recent years.<ref name="Robey"/> For instance, Kol143 (Figure 4) is a compound derived from fungal toxin [https://en.wikipedia.org/wiki/Fumitremorgin fumitremorgin C] (FTC), a selective inhibitor of ABCG2 which exhibits undesirable neurotoxic effects.<ref name="Allen">PMID:12477054</ref> Kol143 was found to be less toxic and more potent than FTC; however, this inhibitor is nonselective toward ABCG2.<ref name="Weidner">PMID:26148857</ref> Various inhibitors were derived from Kol143 with changes made at positions 1 and 2 in Figure 3, which are carbons 3 and 9 respectively. Modifications at these positions prove to affect the inhibitory capacities of compounds. A promising compound which has shown a high degree of potency is the inhibitor MZ29 (Figures 3 and 4).<ref name="Jackson"/>		While ABC transporter inhibition was dismissed after failed clinical trials, interest in revisiting ABC inhibition has reemerged due to new developments made in recent years.<ref name="Robey"/> For instance, Kol143 (Figure 4) is a compound derived from fungal toxin [https://en.wikipedia.org/wiki/Fumitremorgin fumitremorgin C] (FTC), a selective inhibitor of ABCG2 which exhibits undesirable neurotoxic effects.<ref name="Allen">PMID:12477054</ref> Kol143 was found to be less toxic and more potent than FTC; however, this inhibitor is nonselective toward ABCG2.<ref name="Weidner">PMID:26148857</ref> Various inhibitors were derived from Kol143 with changes made at positions 1 and 2 in Figure 3, which are carbons 3 and 9 respectively. Modifications at these positions prove to affect the inhibitory capacities of compounds. A promising compound which has shown a high degree of potency is the inhibitor MZ29 (Figures 3 and 4).<ref name="Jackson"/>

-	ABCG2 inhibitors, <scene name='83/832932/Inhibitor_bound_cavity_1/2'>~~such as~~ MZ29</scene> (Figure 3), bind Cavity 1 and act as competitive inhibitors against ABCG2 substrates and show a higher affinity toward the transporter. Depending on the size of the inhibitor, one or two molecules can accommodate binding to the cavity and form <scene name='83/832932/Inhibitor_interactions_cavity1/3'>hydrogen bonds, van der Waals, and stacking interactions</scene> within the binding site.<ref name="Jackson"/> Many inhibitors are too big to be transported via the leucine plug resulting in the "clogging" of the transporter. With inhibitors acting as wedges, ABCG2 is locked in the inward-facing conformation and unable to transport molecules out of the cell.<ref name="Manolaridis"/>	+	ABCG2 inhibitors, such as <scene name='83/832932/Inhibitor_bound_cavity_1/2'>MZ29</scene> (<scene name='83/832939/Abcg2_bound_to_mz29/3'>close-up MZ29</scene>)(Figure 3), bind Cavity 1 and act as competitive inhibitors against ABCG2 substrates and show a higher affinity toward the transporter. Depending on the size of the inhibitor, one or two molecules can accommodate binding to the cavity and form <scene name='83/832932/Inhibitor_interactions_cavity1/3'>hydrogen bonds, van der Waals, and stacking interactions</scene> within the binding site.<ref name="Jackson"/> Many inhibitors are too big to be transported via the leucine plug resulting in the "clogging" of the transporter. With inhibitors acting as wedges, ABCG2 is locked in the inward-facing conformation and unable to transport molecules out of the cell.<ref name="Manolaridis"/>
	</StructureSection>		</StructureSection>
	== References ==		== References ==

R. Jeremy Johnson at 14:14, 5 May 2020

R. Jeremy Johnson — Tue, 05 May 2020 14:14:25 GMT

←Older revision		Revision as of 14:14, 5 May 2020
Line 30:		Line 30:

	==Disease==		==Disease==
-	[[Image:Ligand_Interactions_6ffc.png\|400 px\|right\|thumb\|Figure 2: MZ29 bound to cavity 1 of ABCG2 [https://www.rcsb.org/structure/6FFC (6FFC)]. Two MZ29 are shown in sticks and are colored by element. Hydrophobic interactions between the surface of cavity 1 and MZ29 are shown in green.]]	+	[[Image:Ligand_Interactions_6ffc.png\|400 px\|right\|thumb\|Figure 3: MZ29 bound to cavity 1 of ABCG2 [https://www.rcsb.org/structure/6FFC (6FFC)]. Two MZ29 are shown in sticks and are colored by element. Hydrophobic interactions between the surface of cavity 1 and MZ29 are shown in green.]]
	Dysfunctions in ABCG2 are linked to [https://en.wikipedia.org/wiki/Hyperuricemia hyperuricemia] which can lead to [https://en.wikipedia.org/wiki/Gout gout], [https://en.wikipedia.org/wiki/Kidney_disease kidney disease], and [https://en.wikipedia.org/wiki/Hypertension hypertension], all of which are thought to be the result of impaired transport of uric acid. Additionally, the expression of ABCG2 has been found to correlate with a poor prognosis and treatment outcome of various cancers including breast, ovarian, and lung.<ref name="Jackson"/>		Dysfunctions in ABCG2 are linked to [https://en.wikipedia.org/wiki/Hyperuricemia hyperuricemia] which can lead to [https://en.wikipedia.org/wiki/Gout gout], [https://en.wikipedia.org/wiki/Kidney_disease kidney disease], and [https://en.wikipedia.org/wiki/Hypertension hypertension], all of which are thought to be the result of impaired transport of uric acid. Additionally, the expression of ABCG2 has been found to correlate with a poor prognosis and treatment outcome of various cancers including breast, ovarian, and lung.<ref name="Jackson"/>

Line 36:		Line 36:
	ABCG2 hinders cancer treatment by contributing to [https://en.wikipedia.org/wiki/Multiple_drug_resistance multidrug resistance] in tumor cells. ABCG2 exports xenbiotics, including vital anti-cancer drugs, which results in the inability to treat cancer cells. Cancer patients often show high levels of expression of multiple ABC transporters. For example, [https://en.wikipedia.org/wiki/Acute_myeloid_leukemia acute myeloid leukemia] (AML) has an increased expression of [https://en.wikipedia.org/wiki/P-glycoprotein ABCB1], [https://en.wikipedia.org/wiki/ABCG1 ABCG1], and ABCG2 while childhood AML shows an increased expression in [https://en.wikipedia.org/wiki/ABCA3 ABCA3], ABCB1, [https://en.wikipedia.org/wiki/ABCC3 ABCC3], and ABCG2.<ref name="Marzac">PMID:21606172</ref><ref name="Bartholomae">PMID:26512967</ref> Additionally, pancreatic cancer has shown an upregulation of [https://en.wikipedia.org/wiki/ABCB4 ABCB4], [https://en.wikipedia.org/wiki/ABCB11 ABCB11], [https://en.wikipedia.org/wiki/ABCC1 ABCC1], ABCC3, [https://en.wikipedia.org/wiki/ABCC5 ABCC5], [https://en.wikipedia.org/wiki/ABCC10 ABCC10], and ABCG2.<ref name="Mohelnikova-Duchonova">PMID:23462326</ref>		ABCG2 hinders cancer treatment by contributing to [https://en.wikipedia.org/wiki/Multiple_drug_resistance multidrug resistance] in tumor cells. ABCG2 exports xenbiotics, including vital anti-cancer drugs, which results in the inability to treat cancer cells. Cancer patients often show high levels of expression of multiple ABC transporters. For example, [https://en.wikipedia.org/wiki/Acute_myeloid_leukemia acute myeloid leukemia] (AML) has an increased expression of [https://en.wikipedia.org/wiki/P-glycoprotein ABCB1], [https://en.wikipedia.org/wiki/ABCG1 ABCG1], and ABCG2 while childhood AML shows an increased expression in [https://en.wikipedia.org/wiki/ABCA3 ABCA3], ABCB1, [https://en.wikipedia.org/wiki/ABCC3 ABCC3], and ABCG2.<ref name="Marzac">PMID:21606172</ref><ref name="Bartholomae">PMID:26512967</ref> Additionally, pancreatic cancer has shown an upregulation of [https://en.wikipedia.org/wiki/ABCB4 ABCB4], [https://en.wikipedia.org/wiki/ABCB11 ABCB11], [https://en.wikipedia.org/wiki/ABCC1 ABCC1], ABCC3, [https://en.wikipedia.org/wiki/ABCC5 ABCC5], [https://en.wikipedia.org/wiki/ABCC10 ABCC10], and ABCG2.<ref name="Mohelnikova-Duchonova">PMID:23462326</ref>

-	The substrate specificity among ABC transporters varies, so this protein family can collectively export a wide variety of substrates and, ultimately, a wide variety of anticancer drugs. ABCG2 has been known to export anticancer drugs such [https://en.wikipedia.org/wiki/Methotrexate methotrexate], [https://en.wikipedia.org/wiki/Mitoxantrone mitoxantrone], [https://en.wikipedia.org/wiki/Topotecan topotecan], [https://en.wikipedia.org/wiki/Irinotecan irinotecan], and [https://en.wikipedia.org/wiki/Alvocidib flavopiridol]<ref name="Mao">PMID:25236865</ref>. Due to the high expression of multiple ABC transporters in cancer cells, simultaneous treatment of multiple transporters would likely be necessary for successful cancer treatment.	+	The substrate specificity among ABC transporters varies, so this protein family can collectively export a wide variety of substrates and, ultimately, a wide variety of anticancer drugs (Figures 3 and 4). ABCG2 has been known to export anticancer drugs such [https://en.wikipedia.org/wiki/Methotrexate methotrexate], [https://en.wikipedia.org/wiki/Mitoxantrone mitoxantrone], [https://en.wikipedia.org/wiki/Topotecan topotecan], [https://en.wikipedia.org/wiki/Irinotecan irinotecan], and [https://en.wikipedia.org/wiki/Alvocidib flavopiridol]<ref name="Mao">PMID:25236865</ref>. Due to the high expression of multiple ABC transporters in cancer cells, simultaneous treatment of multiple transporters would likely be necessary for successful cancer treatment.

	===Inhibitors===		===Inhibitors===
-	[[Image:kol143 and mz29 abcg2 inhibitors.png\|250 px\|right\|thumb\|Figure 3. (Top) Known ABCG2 Inhibitor Kol143; Red numbers indicate points of alternation in derivatives of inhibitor. (Bottom) Derivative of Kol143, MZ29.]]	+	[[Image:kol143 and mz29 abcg2 inhibitors.png\|250 px\|right\|thumb\|Figure 4. (Top) Known ABCG2 Inhibitor Kol143; Red numbers indicate points of alternation in derivatives of inhibitor. (Bottom) Derivative of Kol143, MZ29.]]
	Due to the potential for ABCG2 inhibition to aid in cancer treatment, efforts have been made to develop specific inhibitors of ABCG2 and other ABC transporters. The ABC transporter ABCB1, also known as multidrug resistance 1 (MDR1), was a therapeutic target in previous studies which produced three generations of MDR1 inhibitors, such as [https://en.wikipedia.org/wiki/Verapamil verapamil], [https://en.wikipedia.org/wiki/Valspodar valspodar], and [https://en.wikipedia.org/wiki/Zosuquidar zosuquidar]; however, many of these inhibitors had neurotoxic effects that discouraged their use in cancer treatment.<ref name="Leonard">PMID:14530494</ref><ref name="Binkhathlan">PMID:23369096</ref><ref name="Witherspoon">PMID:9816083</ref>		Due to the potential for ABCG2 inhibition to aid in cancer treatment, efforts have been made to develop specific inhibitors of ABCG2 and other ABC transporters. The ABC transporter ABCB1, also known as multidrug resistance 1 (MDR1), was a therapeutic target in previous studies which produced three generations of MDR1 inhibitors, such as [https://en.wikipedia.org/wiki/Verapamil verapamil], [https://en.wikipedia.org/wiki/Valspodar valspodar], and [https://en.wikipedia.org/wiki/Zosuquidar zosuquidar]; however, many of these inhibitors had neurotoxic effects that discouraged their use in cancer treatment.<ref name="Leonard">PMID:14530494</ref><ref name="Binkhathlan">PMID:23369096</ref><ref name="Witherspoon">PMID:9816083</ref>

-	While ABC transporter inhibition was dismissed after failed clinical trials, interest in revisiting ABC inhibition has reemerged due to new developments made in recent years.<ref name="Robey"/> For instance, Kol143 (Figure 3) is a compound derived from fungal toxin [https://en.wikipedia.org/wiki/Fumitremorgin fumitremorgin C] (FTC), a selective inhibitor of ABCG2 which exhibits undesirable neurotoxic effects.<ref name="Allen">PMID:12477054</ref> Kol143 was found to be less toxic and more potent than FTC; however, this inhibitor is nonselective toward ABCG2.<ref name="Weidner">PMID:26148857</ref> Various inhibitors were derived from Kol143 with changes made at positions 1 and 2 in Figure 3, which are carbons 3 and 9 respectively. Modifications at these positions prove to affect the inhibitory capacities of compounds. A promising compound which has shown a high degree of potency is the inhibitor MZ29 (~~Figure~~ 3).<ref name="Jackson"/>	+	While ABC transporter inhibition was dismissed after failed clinical trials, interest in revisiting ABC inhibition has reemerged due to new developments made in recent years.<ref name="Robey"/> For instance, Kol143 (Figure 4) is a compound derived from fungal toxin [https://en.wikipedia.org/wiki/Fumitremorgin fumitremorgin C] (FTC), a selective inhibitor of ABCG2 which exhibits undesirable neurotoxic effects.<ref name="Allen">PMID:12477054</ref> Kol143 was found to be less toxic and more potent than FTC; however, this inhibitor is nonselective toward ABCG2.<ref name="Weidner">PMID:26148857</ref> Various inhibitors were derived from Kol143 with changes made at positions 1 and 2 in Figure 3, which are carbons 3 and 9 respectively. Modifications at these positions prove to affect the inhibitory capacities of compounds. A promising compound which has shown a high degree of potency is the inhibitor MZ29 (Figures 3 and 4).<ref name="Jackson"/>

-	ABCG2 inhibitors, <scene name='83/832932/Inhibitor_bound_cavity_1/2'>such as MZ29</scene>, bind Cavity 1 and act as competitive inhibitors against ABCG2 substrates and show a higher affinity toward the transporter. Depending on the size of the inhibitor, one or two molecules can accommodate binding to the cavity and form <scene name='83/832932/Inhibitor_interactions_cavity1/3'>hydrogen bonds, van der Waals, and stacking interactions</scene> within the binding site.<ref name="Jackson"/> Many inhibitors are too big to be transported via the leucine plug resulting in the "clogging" of the transporter. With inhibitors acting as wedges, ABCG2 is locked in the inward-facing conformation and unable to transport molecules out of the cell.<ref name="Manolaridis"/>	+	ABCG2 inhibitors, <scene name='83/832932/Inhibitor_bound_cavity_1/2'>such as MZ29</scene> (Figure 3), bind Cavity 1 and act as competitive inhibitors against ABCG2 substrates and show a higher affinity toward the transporter. Depending on the size of the inhibitor, one or two molecules can accommodate binding to the cavity and form <scene name='83/832932/Inhibitor_interactions_cavity1/3'>hydrogen bonds, van der Waals, and stacking interactions</scene> within the binding site.<ref name="Jackson"/> Many inhibitors are too big to be transported via the leucine plug resulting in the "clogging" of the transporter. With inhibitors acting as wedges, ABCG2 is locked in the inward-facing conformation and unable to transport molecules out of the cell.<ref name="Manolaridis"/>
	</StructureSection>		</StructureSection>
	== References ==		== References ==

R. Jeremy Johnson at 14:12, 5 May 2020

R. Jeremy Johnson — Tue, 05 May 2020 14:12:07 GMT

←Older revision		Revision as of 14:12, 5 May 2020
Line 30:		Line 30:

	==Disease==		==Disease==
		+	[[Image:Ligand_Interactions_6ffc.png\|400 px\|right\|thumb\|Figure 2: MZ29 bound to cavity 1 of ABCG2 [https://www.rcsb.org/structure/6FFC (6FFC)]. Two MZ29 are shown in sticks and are colored by element. Hydrophobic interactions between the surface of cavity 1 and MZ29 are shown in green.]]
	Dysfunctions in ABCG2 are linked to [https://en.wikipedia.org/wiki/Hyperuricemia hyperuricemia] which can lead to [https://en.wikipedia.org/wiki/Gout gout], [https://en.wikipedia.org/wiki/Kidney_disease kidney disease], and [https://en.wikipedia.org/wiki/Hypertension hypertension], all of which are thought to be the result of impaired transport of uric acid. Additionally, the expression of ABCG2 has been found to correlate with a poor prognosis and treatment outcome of various cancers including breast, ovarian, and lung.<ref name="Jackson"/>		Dysfunctions in ABCG2 are linked to [https://en.wikipedia.org/wiki/Hyperuricemia hyperuricemia] which can lead to [https://en.wikipedia.org/wiki/Gout gout], [https://en.wikipedia.org/wiki/Kidney_disease kidney disease], and [https://en.wikipedia.org/wiki/Hypertension hypertension], all of which are thought to be the result of impaired transport of uric acid. Additionally, the expression of ABCG2 has been found to correlate with a poor prognosis and treatment outcome of various cancers including breast, ovarian, and lung.<ref name="Jackson"/>

R. Jeremy Johnson at 14:09, 5 May 2020

R. Jeremy Johnson — Tue, 05 May 2020 14:09:11 GMT

←Older revision		Revision as of 14:09, 5 May 2020
Line 15:		Line 15:

	===ATP Bound and Unbound Conformations===		===ATP Bound and Unbound Conformations===
-	As an [https://en.wikipedia.org/wiki/ATP-binding_cassette_transporter ABC Transporter], ABCG2 exhibits ATPase activity by using the energy of ATP hydrolysis to facilitate transport. After substrates bind in the TMD, one molecule of <scene name='83/832932/Atp_bound_use2/3'>ATP binds each NBD</scene> (2 molecules of ATP total) causing a conformational change of the overall structure from an <scene name='83/832932/Overall_use_2/3'>inward-facing conformation</scene> to an <scene name='83/832932/Outward_facing_conformation/4'>outward-facing conformation</scene>. ATP coordinates with various residues and a magnesium ion in the <scene name='83/832932/Atp_bound_in_nbd/2'>binding site of each NBD</scene> which is bordered with [https://en.wikipedia.org/wiki/Walker_motifs Walker A and B motifs]. One molecule of ATP is hydrolyzed to transport substrates across the cell membrane while the second molecule of ATP is hydrolyzed to reset the transporter to its inward-facing conformation.<ref name="Robey"~~>PMID:29643473<~~/~~ref~~>	+	As an [https://en.wikipedia.org/wiki/ATP-binding_cassette_transporter ABC Transporter], ABCG2 exhibits ATPase activity by using the energy of ATP hydrolysis to facilitate transport. After substrates bind in the TMD, one molecule of <scene name='83/832932/Atp_bound_use2/3'>ATP binds each NBD</scene> (2 molecules of ATP total) causing a conformational change of the overall structure from an <scene name='83/832932/Overall_use_2/3'>inward-facing conformation</scene> to an <scene name='83/832932/Outward_facing_conformation/4'>outward-facing conformation</scene>. <scene name='83/832937/Atp_and_mg_bound_to_abcg2/4'>ATP coordinates</scene> with various residues and a magnesium ion in the <scene name='83/832932/Atp_bound_in_nbd/2'>binding site of each NBD</scene> which is bordered with [https://en.wikipedia.org/wiki/Walker_motifs Walker A and B motifs]. One molecule of ATP is hydrolyzed to transport substrates across the cell membrane while the second molecule of ATP is hydrolyzed to reset the transporter to its inward-facing conformation.<ref name="Robey"/>

	When ATP binds, α-helices in the NBD <scene name='83/832932/Atp_bound_nbd/3'>rotate</scene> approximately 35° relative to the <scene name='83/832932/Overall_structure_nbd_unbound/5'>inward-facing conformation of NBD</scene>. This shift in the NBD causes slight shifts of α-helices in the TMD; these helices are <scene name='83/832932/Atp_bound_use_tmd/4'>pushed toward each other</scene> relative to the <scene name='83/832932/Overall_structure_tmd_unbound/4'>inward-facing conformation of TMD</scene>. The overall shift from inward-facing to outward-facing promotes the transport of substrates through the transporter.<ref name="Manolaridis"/>		When ATP binds, α-helices in the NBD <scene name='83/832932/Atp_bound_nbd/3'>rotate</scene> approximately 35° relative to the <scene name='83/832932/Overall_structure_nbd_unbound/5'>inward-facing conformation of NBD</scene>. This shift in the NBD causes slight shifts of α-helices in the TMD; these helices are <scene name='83/832932/Atp_bound_use_tmd/4'>pushed toward each other</scene> relative to the <scene name='83/832932/Overall_structure_tmd_unbound/4'>inward-facing conformation of TMD</scene>. The overall shift from inward-facing to outward-facing promotes the transport of substrates through the transporter.<ref name="Manolaridis"/>
		+
		+	The NBDs in ABCG2 remain in contact with one another even without a bound substrate, providing greater substrate specificity as the entrance to the transporter is not as globular as other ABC transporters like ABCB1 or ABCC1. The entrance from the cytoplasm to the transporter is lined by [https://en.wikipedia.org/wiki/Hydrophobe hydrophobic] residues<scene name='83/832939/Lining_of_entrance_of_nbd/1'> A397, V401, L405, L539, I543 and T547</scene> in both [https://en.wikipedia.org/wiki/Monomer monomers]. Dimerization of ABCG2 was originally hypothesized to require a <scene name='83/832939/Disproved_dimerization_process/1'>406xxx410 structural motif</scene> in each of the two domains. Cryo-EM structures however showed that these structural [https://en.wikipedia.org/wiki/Sequence_motif motifs] were on opposite sides of the protein.<ref name="Manolaridis" /> <ref name="Jackson">PMID:29610494</ref>

	===Cavities and Leucine Plug===		===Cavities and Leucine Plug===
Line 28:		Line 30:

	==Disease==		==Disease==
-	Dysfunctions in ABCG2 are linked to [https://en.wikipedia.org/wiki/Hyperuricemia hyperuricemia] which can lead to [https://en.wikipedia.org/wiki/Gout gout], [https://en.wikipedia.org/wiki/Kidney_disease kidney disease], and [https://en.wikipedia.org/wiki/Hypertension hypertension], all of which are thought to be the result of impaired transport of uric acid. Additionally, the expression of ABCG2 has been found to correlate with a poor prognosis and treatment outcome of various cancers including breast, ovarian, and lung.<ref name="Jackson"~~>PMID:29610494<~~/~~ref~~>	+	Dysfunctions in ABCG2 are linked to [https://en.wikipedia.org/wiki/Hyperuricemia hyperuricemia] which can lead to [https://en.wikipedia.org/wiki/Gout gout], [https://en.wikipedia.org/wiki/Kidney_disease kidney disease], and [https://en.wikipedia.org/wiki/Hypertension hypertension], all of which are thought to be the result of impaired transport of uric acid. Additionally, the expression of ABCG2 has been found to correlate with a poor prognosis and treatment outcome of various cancers including breast, ovarian, and lung.<ref name="Jackson"/>

	===Cancer===		===Cancer===